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ABSTRACT
Objectives: To develop evidence-based recommenda-
tions for the use of methotrexate in daily clinical practice
in rheumatic disorders.
Methods: 751 rheumatologists from 17 countries
participated in the 3E (Evidence, Expertise, Exchange)
Initiative of 2007–8 consisting of three separate rounds of
discussions and Delphi votes. Ten clinical questions
concerning the use of methotrexate in rheumatic
disorders were formulated. A systematic literature search
in Medline, Embase, Cochrane Library and 2005–7
American College of Rheumatology/European League
Against Rheumatism meeting abstracts was conducted.
Selected articles were systematically reviewed and the
evidence was appraised according to the Oxford levels of
evidence. Each country elaborated a set of national
recommendations. Finally, multinational recommendations
were formulated and agreement among the participants
and the potential impact on their clinical practice was
assessed.
Results: A total of 16 979 references was identified, of
which 304 articles were included in the systematic
reviews. Ten multinational key recommendations on the
use of methotrexate were formulated. Nine recommen-
dations were specific for rheumatoid arthritis (RA),
including the work-up before initiating methotrexate,
optimal dosage and route, use of folic acid, monitoring,
management of hepatotoxicity, long-term safety, mono
versus combination therapy and management in the
perioperative period and before/during pregnancy. One
recommendation concerned methotrexate as a steroid-
sparing agent in other rheumatic diseases.
Conclusions: Ten recommendations for the use of
methotrexate in daily clinical practice focussed on RA
were developed, which are evidence based and supported
by a large panel of rheumatologists, enhancing their
validity and practical use.
Methotrexate is the disease-modifying antirheu-
matic drug (DMARD) of first choice in the
treatment of rheumatoid arthritis (RA) and is also
used in other systemic rheumatic disorders.
12
Despite its widespread use and more than two
decades of experience, considerable variation exists
among rheumatologists in prescribing methotrex-
ate, including the dosage, folic acid supplementa-
tion and safety monitoring.
34In addition, little is
known about the optimal management of metho-
trexate in specific clinical situations such as the
perioperative period and before/during pregnancy.
Existing guidelines often lack this level of detail.
5
The 3E Initiative (Evidence, Expertise, Exchange)
in rheumatology is a multinational effort, aimed at
promoting evidence-based medicine, by formulat-
ing detailed recommendations addressing clinical
problems.
6 In contrast to guidelines developed by a
limited panel of experts, the 3E Initiative involves a
broad international panel of practising rheumatol-
ogists. Furthermore, the initiative promotes epide-
miology, by teaching and conducting systematic
literature research following a strict methodology.
7
Therefore, the objective of the 3E Initiative of
2007–8 was to develop practical recommendations
for the use of methotrexate in rheumatic disorders,
by integrating systematically generated evidence
and expert opinion of a broad panel of interna-
tional rheumatologists.
METHODS
A total of 751 rheumatologists from 17 countries
participated in the 3E Initiative of 2007–8. Each
country was represented by a scientific committee,
consisting of one principal investigator and five to
16 members. The bibliographic team consisted of
six international fellows (WK, EL, JAM-L, CS, JT,
KV), three mentors (CB, LC, DvdH) and the
scientific organiser (MD). During the first interna-
tional meeting (n = 87 participants), 10 clinically
relevant questions on the use of methotrexate in
rheumatic disorders were formulated and selected
by a Delphi vote. The areas addressed were, for RA:
preadministration work-up, optimal dosage and
route, use of folic acid, safety monitoring, hepato-
toxicity (also for psoriatic arthritis (PsA)), long-
term safety (.2 years), mono versus combination
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during pregnancy, and methotrexate as a steroid-sparing agent
in other rheumatic disorders.
The bibliographic team conducted a systematic literature
review, following the updated guidelines of the Cochrane
Collaboration.
7 Each question was rephrased according to the
PICO (population, intervention, comparison, outcome) method
with the population defined as adult RA, PsA or other rheumatic
diseases, and specific interventions, comparisons and outcomes
defined according to each question.
8 Comprehensive search
strategies were developed in collaboration with experienced
librarians, including terms for methotrexate, RA and specific
key words, without language restriction. Subsequently, Medline,
Embase, Cochrane Library and European League Against
Rheumatism (EULAR) 2005–7 and American College of
Rheumatology (ACR) 2005–6 abstracts were systematically
searched for articles published up to September 2007. Additional
references were identified by a hand search. Articles were selected
applying predefined inclusion and exclusion criteria and their
methodological quality was graded according to the levels of
evidence of the Oxford Centre for Evidence-Based Medicine.
9 For
each question, relevant data were extracted and appropriate
statistics were calculated, including effect sizes, hazard ratios
(HR), and standardised mortality ratios with 95% CI. If possible,
meta-analyses were conducted using RevMan 4.2.10, calculating
odds ratios (OR) with fixed effects and relative risks (RR) with a
random effects model.
In the second round, a national meeting was held in each
country (total n = 751 participants) to discuss the generated
evidence and propose a set of recommendations. In a third joint
meeting, the scientific committees (n = 94 participants)
merged all propositions to 10 final recommendations by
discussion and Delphi vote. The grade of recommendation
according to the Oxford Levels of Evidence was assessed and the
level of agreement was measured on a 10-point visual analogue
scale (1, no agreement; 10, full agreement).
10 Finally, the
potential impact among the participants was assessed using
three statements: ‘‘this recommendation will change my
practice’’; ‘‘this recommendation will not change my practice
as it is already my practice’’; ‘‘this recommendation will not
change my practice as I don’t want to change my practice for
this aspect’’.
RESULTS
A total of 16 979 references was identified, of which 304 articles
were systematically reviewed (table 1). The 10 multinational
key recommendations are listed in table 2, with the correspond-
ing level of evidence and grade of recommendation. The mean
level of agreement among the rheumatologists was 8.1 (range
7.4–8.8). The percentage of rheumatologists who indicated that
they would change their clinical practice according to each
recommendation is shown in table 3.
Recommendation 1
The work-up for patients starting methotrexate should include
a clinical assessment of risk factors for methotrexate toxicity
(including alcohol intake), patient education, aspartate amino-
transferase (AST), alanine aminotransferase (ALT), albumin,
complete blood count (CBC), creatinine, chest x ray (obtained
within the previous year); consider serology for HIV, hepatitis
B/C, blood fasting glucose, lipid profile and pregnancy test.
The evidence needed to decide whether to start a patient with
RA on methotrexate or not might be extrapolated from data on
risk factors for severe toxicity. These data suggest that an
estimated creatinine clearance of less than 79 ml/minute
increases severe methotrexate (pulmonary) toxicity and that
hypoalbuminaemia is associated with methotrexate-induced
thrombocytopenia, liver and pulmonary toxicity.
11–15 In addi-
tion, lung abnormalities on radiographs, but not pulmonary
function tests, are predictive of the development of methotrex-
ate-induced pneumonitis.
16–18 Additional subgroups at risk of
exacerbation of hepatic disease with methotrexate are obese
patients, patients with diabetes and patients with viral or
alcoholic hepatitis.
19–23 This observational evidence was com-
bined with expert opinion, following from contraindications to
methotrexate use frequently listed in randomised controlled
trials (RCT) in RA from the past 15 years: significant renal
disease, hepatic disorders, leucopenia less than 3.0 610
9/l,
thrombocytopenia less than 100 610
9/l, age greater than
70 years, malignancy, pregnancy or inadequate contraception,
history of alcohol/drug abuse, acute or chronic infection and
pulmonary disease. Finally, four national recommendations
from Austria, Germany, The Netherlands and Spain and the
1996 ACR guidelines on monitoring RA treatment, all suggest
creatinine, CBC, AST/ALT with or without alkaline phospha-
tase, albumin, hepatitis B/C serology and a chest radiograph for
the preadministration work-up.
24
Recommendation 2
Oral methotrexate should be started at 10–15 mg/week, with
escalation of 5 mg every 2–4 weeks up to 20–30 mg/week,
depending on clinical response and tolerability; parenteral
administration should be considered in the case of inadequate
clinical response or intolerance.
The results of three RCT directly comparing different dosages
of oral methotrexate in RA showed dose-dependent efficacy and
toxicity.
25–27 A starting dose of 25 mg/week compared with
15 mg/week was more effective, but with a trend towards more
gastrointestinal toxicity.
26 Starting doses of 12.5–20 mg/week
versus 5–10 mg/week resulted in higher clinical efficacy, with-
out more toxicity.
25 Rapid dose escalation of 5 mg/month to 25–
30 mg/week was associated with higher efficacy, but also with
more adverse events, in comparison with slow escalation of
5 mg/3 months.
27 Regarding the optimal route of administra-
tion, retrospective studies suggest higher efficacy and less
gastrointestinal toxicity with parenteral versus oral methotrex-
ate,
28 29 which might be explained by the greater bioavailability
of the parenteral form.
30 31 Indeed, the single RCT that
compared 15 mg/week subcutaneous with oral methotrexate
Table 1 Results of the systematic literature search for each
recommendation topic
Retrieved references
by systematic
literature search (n)
Articles included in
the systematic
reviews (n)
Pre-methotrexate work-up 1214 52
Dosage and route 1748 50
Folic acid 334 9
Monitoring 857 23
Hepatotoxicity 426 46
Long-term safety 2449 88
Mono vs combination 6958 20
Steroid-sparing agent 527 6
Perioperative period 303 4
Pregnancy 2163 6
Total 16 979 304
Recommendation
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result of toxicity with subcutaneous methotrexate in early
methotrexate-naive RA patients.
32 In contrast, in RA patients
who failed methotrexate 15–20 mg/week plus other DMARD,
neither a switch to 15 mg/week administered intramuscularly,
nor subsequent dose escalation resulted in increased efficacy.
33
In conclusion, the experts preferred the oral route, dosed
according to the recommendation, with a possible switch to
parenteral in case of an insufficient response at the highest
tolerable dose.
Recommendation 3
Prescription of at least 5 mg folic acid per week with
methotrexate therapy is strongly recommended.
A meta-analysis of nine studies including 788 RA patients
suggested that folic acid supplementation reduces gastrointest-
inal and liver toxicity of methotrexate, without reducing
efficacy.
34 Four studies using folic acid 7–35 mg/week showed
a significant reduction in the risk of gastrointestinal side effects
(OR 0.42; 95% CI 0.21 to 0.85),
35–38 in contrast with only one
study using 5 mg/week folic acid, which did not reach
significance.
37 After further stratification, however, the protec-
tive effect was only significant in the two studies that used
methotrexate at less than 10 mg/week (OR 0.21; 95% CI 0.07 to
0.69)
36 37 and not in the two largest studies using methotrexate
14–18 mg/week (OR 0.61; 95% CI 0.25 to 1.48).
35 38 The two
studies in which hepatotoxicity was analysed showed a
significant protective effect with 1 mg/day folic acid (OR
0.17; 95% CI 0.09 to 0.32], irrespective of the methotrexate
dose.
35 36 Only folinic acid at doses of 5 mg/week or less
significantly decreased gastrointestinal side effects and hepato-
toxicity (OR 0.39; 95% CI 0.2 to 0.76 and OR 0.16; 95% CI 0.09
to 0.29, respectively).
35 39–41 Furthermore, folinic acid at greater
than 5 mg/week was associated with a significant increase in
Table 2 Multinational recommendations for the use of methotrexate in RA (1–7, 9–10) and other rheumatic disorders (8)
Recommendation
Level of
evidence
Grade of
recommendation
Agreement
mean (SD)
1 The work-up for patients starting methotrexate should include clinical assessment of risk factors for
methotrexate toxicity (including alcohol intake), patient education, AST, ALT, albumin, CBC, creatinine, chest
x ray (obtained within the previous year); consider serology for HIV, hepatitis B/C, blood fasting glucose, lipid
profile and pregnancy test.
4 C 8.2 (1.9)
2 Oral methotrexate should be started at 10–15 mg/week, with escalation of 5 mg every 2–4 weeks up to 20–
30 mg/week, depending on clinical response and tolerability; parenteral administration should be considered
in the case of inadequate clinical response or intolerance.
2b B 7.8 (2.6)
3 Prescription of at least 5 mg folic acid per week with methotrexate therapy is strongly recommended. 1a– A 7.5 (2.7)
4 When starting methotrexate or increasing the dose, ALT with or without AST, creatinine and CBC should be
performed every 1–1.5 months until a stable dose is reached and every 1–3 months thereafter; clinical
assessment for side effects and risk factors should be performed at each visit.
4 C 8.1 (2.1)
5 Methotrexate should be stopped if there is a confirmed increase in ALT/AST greater than three times the
ULN, but may be reinstituted at a lower dose following normalisation. If the ALT/AST levels are persistently
elevated up to three times the ULN, the dose of methotrexate should be adjusted; diagnostic procedures
should be considered in the case of persistently elevated ALT/AST more than three times the ULN after
discontinuation.
2b C 7.4 (2.3)
6 Based on its acceptable safety profile, methotrexate is appropriate for long-term use. 2b B 8.7 (1.9)
7 In DMARD-naive patients the balance of the efficacy/toxicity favours methotrexate monotherapy over
combination with other conventional DMARD; methotrexate should be considered as the anchor for
combination therapy when methotrexate monotherapy does not achieve disease control.
1a– A 8.3 (2.1)
8 Methotrexate, as a steroid-sparing agent, is recommended in giant-cell arteritis and polymyalgia rheumatica
and can be considered in patients with systemic lupus erythematosus or (juvenile) dermatomyositis.
1b B 7.7 (2.1)
9 Methotrexate can be safely continued in the perioperative period in RA patients undergoing elective
orthopaedic surgery.
1b B 8.8 (1.9)
10 Methotrexate should not be used for at least 3 months before planned pregnancy for men and women and
should not be used during pregnancy or breast feeding.
4 C 8.2 (2.7)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; ULN, upper
limit of normal.
Table 3 Percentage of rheumatologists in the 3E Initiative who indicated for each recommendation if it
would change their clinical practice
Recommendation
(number and topic)
The recommendation
will change my
practice
(%)
The recommendation
is already my
practice
(%)
I don’t want to
change my practice
for this aspect
(%)
1 Pre-methotrexate work-up 29.8 61.2 9.0
2 Dosage and route 16.2 68.7 15.1
3 Folic acid 15.3 78.6 6.1
4 Monitoring 21.1 53.5 25.4
5 Hepatotoxicity 16.5 68.0 15.5
6 Long-term safety 2.0 96.0 2.0
7 Mono vs combination 5.0 86.9 8.1
8 Steroid-sparing agent 25.6 67.1 7.3
9 Perioperative period 41.3 46.7 12.0
10 Pregnancy 19.5 71.3 9.2
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to 10.90 and OR 5.3; 95% CI 0.03 to 10.58, respectively),
whereas folic acid or low dosages ((5 mg/week) of folinic acid
were not.
39 42 43 In conclusion, the experts favoured folic acid and
recommended at least 5 mg/week, taking into account the
potential need for higher dosages, with the currently higher
dosed methotrexate.
Recommendation 4
When starting methotrexate or increasing the dose, ALT with or
without AST, creatinine and CBC should be performed every 1–
1.5 months until a stable dose is reached and every 1–3 months
thereafter; clinical assessment for side effects and risk factors
should be performed at each visit.
Both the mean AST and the percentage of elevated AST have
been reported to correlate with histological grades of liver
disease in RA.
15 44–47 The 1994 ACR guidelines for monitoring
hepatotoxicity showed 80% sensitivity and 82% specificity for
detecting fibrosis/cirrhosis of serial abnormal AST tests, with
fewer costs and complications compared with routine liver
biopsy.
48 49 One study suggests that ALT alone might detect
90% of the elevated AST or paired tests.
50 In contrast, alkaline
phosphatase seems oversensitive for monitoring hepatotoxi-
city.
48 In addition to transaminases, renal function should be
monitored, as it is associated with increased (pulmonary)
toxicity and CBC is required to monitor haematological
toxicity.
11 51 Less evidence is available on the frequency of
monitoring, although two observational studies showed an
optimal interval for identifying abnormal liver enzymes of 30–
60 days and a decreasing incidence of abnormal liver enzymes in
the first months of methotrexate therapy.
48 52 Accordingly, the
four national recommendations and the 1996 ACR guidelines
suggest monitoring every 1–3 months, with initially more
frequent assessments.
24
Recommendation 5
Methotrexate should be stopped if there is a confirmed increase
in ALT/AST greater than three times the upper limit of normal
(ULN), but may be reinstituted at a lower dose following
normalisation. If the ALT/AST levels are persistently elevated
up to three times the ULN, the dose of methotrexate should be
adjusted; diagnostic procedures should be considered in the case
of persistent elevated ALT/AST more than three times the ULN
after discontinuation.
Pooled data of 2062 RA patients after a mean of 3.3 years on
methotrexate showed that the cumulative incidence of abnor-
mal ALT/AST was 48.9% above the ULN and 16.8% above two
to three times the ULN.
53 Methotrexate was frequently
continued without a dose change, but the frequency of
(spontaneous) normalisation was insufficiently reported. In
addition, pooled percentages of mild and severe fibrosis and
cirrhosis in 1113 RA patients after a mean of 4.1 years on
methotrexate were 15.3%, 1.3% and 0.5%, respectively.
However, the results of pre-methotrexate biopsies already
showed a prevalence of 9.1% mild fibrosis and 0.3% cirrhosis.
53
For PsA, a somewhat higher incidence of elevated liver enzymes
and fibrosis/cirrhosis compared with RA was found, but the
evidence is very limited.
21 54–57 For RA, the evidence suggests that
liver enzyme elevation is frequent but often transient, that
multiple rather than single findings associate with an abnormal
biopsy (as noted earlier) and that methotrexate-induced
fibrosis/cirrhosis is rare. The experts emphasised considering
other causal factors, including non-steroidal anti-inflammatory
drugs, obesity and alcohol and other diagnostic procedures than
liver biopsy in the case of persistently elevated liver enzymes
after the discontinuation of methotrexate.
22 44 58
Recommendation 6
Based on its acceptable safety profile, methotrexate is appro-
priate for long-term use.
RA patients have an increased mortality rate compared with
the general population (standardised mortality ratio 1.9; 95% CI
1.3 to 2.8).
59 However, RA patients on methotrexate compared
with patients without methotrexate had a lower mortality
incidence rate (23/1000 versus 26.7/1000 patient-years) and
reduced cardiovascular mortality (HR 0.3; 95% CI 0.2 to 0.7) in
a large 6-year prospective study.
60 In addition, in two case–
control studies, methotrexate was not a risk factor and even
reduced the risk of cardiovascular disease, respectively (OR 0.11;
95% CI 0.02 to 0.56).
61 62 In a meta-analysis and several cohorts
with 5–12 years follow-up, methotrexate was less often
discontinued because of toxicity than other DMARD, except
for hydroxychloroquine.
63 64 Gastrointestinal events and ele-
vated liver enzymes are the most frequently encountered
toxicities.
64 However, as discussed earlier, the risk of severe
fibrosis and cirrhosis seems low. Long-term methotrexate use
was not associated with an increased risk of serious infections
(HR 0.91; 95% CI 0.57 to 1.45), including herpes zoster (HR 1.0;
95% CI 0.8 to 1.3).
65 66 Although RA patients have an increased
risk of lymphoma compared with the general population,
evidence on the risk of methotrexate use independent of RA is
inconclusive, because studies did not address RA as the reference
population and the risk was not adjusted for disease severity.
67 68
Five case reports suggest that methotrexate might be associated
with Epstein–Barr virus-related lymphoproliferative disease and
regression after methotrexate withdrawal.
69–73
Recommendation 7
In DMARD-naive patients the balance of efficacy/toxicity
favours methotrexate monotherapy over combination with
other conventional DMARD; methotrexate should be consid-
ered as the anchor for combination therapy when methotrexate
monotherapy does not achieve disease control.
A meta-analysis of 20 RCT evaluated methotrexate mono
versus combination therapy in RA, excluding combinations
with corticosteroids or biological agents.
74 Analyses were
stratified for DMARD-naive patients and patients with an
inadequate response to previous methotrexate or other
DMARD. Methotrexate combination therapy was superior to
methotrexate monotherapy mainly in patients with a previous
inadequate response to methotrexate, resulting in significantly
more ACR20 (RR 2.51; 95% CI 1.92 to 3.28), ACR50 (RR 4.54;
95% CI 2.51 to 8.2) and ACR70 (RR 5.59; 95% CI 2.08 to 15.01)
responses.
75–78 In contrast, in patients who failed other DMARD,
only significantly more ACR20 responses (RR 1.85; 95% CI 1.21
to 2.83) were seen with combination therapy and a trend for
more EULAR good response and remission.
79 80 In DMARD-
naive patients, combination therapy showed a trend for more
EULAR moderate response and remission, but only ACR70
responses were significantly more often achieved (RR 2.41; 95%
CI 1.07 to 5.44).
81–85 Regarding toxicity, methotrexate combined
with sulfasalazine and methotrexate combined with lefluno-
mide each significantly increased the risk of gastrointestinal side
effects and hepatotoxicity, with a trend towards more with-
drawal as a result of toxicity.
76 79 81 82 86 87 In contrast, metho-
trexate combined with sulfasalazine and hydroxychloroquine
Recommendation
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88
Weighing efficacy and toxicity, the experts favoured metho-
trexate monotherapy over the combination with conventional
DMARD in DMARD-naive RA patients. As such, the recom-
mendation does not contradict the well-established superiority
of combination therapies including either prednisone or anti-
tumour necrosis factor.
89–92
Recommendation 8
Methotrexate, as a steroid-sparing agent, is recommended in
giant-cell arteritis and polymyalgia rheumatica and can be
considered in patients with systemic lupus erythematosus or
(juvenile) dermatomyositis.
An individual patient data meta-analysis evaluated the
steroid-sparing effect of methotrexate 7.5–17.5 mg/week versus
placebo in giant-cell arteritis patients on high-dose prednisone.
93
The results showed a higher prednisone discontinuation rate
(HR 2.84; 95% CI 1.52 to 5.28), significantly lower cumulative
steroid dose and fewer relapses with methotrexate therapy after
1 year. Two RCT in polymyalgia rheumatica also showed
significantly more prednisone discontinuation with methotrex-
ate 10 mg/week compared with placebo, significantly fewer
relapses and a trend towards lower prednisone duration and
cumulative dose.
94 95 Systemic lupus erythematosus patients in
two RCT evaluating methotrexate 7.5–20 mg/week versus
placebo had significantly more prednisone reduction, fewer
skin and joint flares, but more adverse events with methotrex-
ate therapy.
96 97 Finally, in a cohort study, juvenile dermato-
myositis patients discontinued prednisone significantly earlier
and had significantly lower cumulative prednisone doses with
concomitant methotrexate therapy, but without an additional
beneficial effect on disease activity.
98 No studies were found
comparing the steroid-sparing effect of methotrexate with other
DMARD.
Recommendation 9
Methotrexate can be safely continued in the perioperative
period in RA patients undergoing elective orthopaedic surgery.
Four studies evaluated stopping or continuing methotrexate
one or more weeks before elective orthopaedic surgery in RA. In
one RCT, no differences in postoperative complications were
observed between patients who continued or stopped metho-
trexate (mean dose 10 mg/week).
99 In a second RCT, patients
who continued methotrexate (mean dose 10 mg/week) reported
significantly fewer RA flares than patients who stopped
methotrexate.
100 In contrast, in a prospective cohort study
postoperative infections occurred in 30% of patients who
continued methotrexate compared with none of the patients
who stopped methotrexate, without postoperative flares of RA
in either group.
101 However, a multivariate analysis in another
cohort study showed that the perioperative use of methotrexate
was not associated with wound morbidity (p=0.84) and
significantly reduced RA flares.
102 Although these studies
suggest that methotrexate can be safely continued in the
perioperative period of elective orthopaedic surgery, no studies
were found regarding (non-)elective non-orthopaedic surgery.
Recommendation 10
Methotrexate should not be used for at least 3 months before
planned pregnancy for men and women and should not be used
during pregnancy or breast feeding.
Six studies assessed the outcome of continued methotrexate
therapy before/during pregnancy in (mostly) RA patients by
surveys and database searches.
103–108 A total of 101 pregnancies
was exposed to methotrexate during pregnancy (n = 92) or
before conception (n = 9). Eighteen induced abortions were
reported, but the reasons were not stated. A total of 20 (24%)
miscarriages, five (6%) congenital malformations and 62 (75%)
live births was reported, with one (1%) patient lost to follow-
up. In healthy women, corresponding percentages are 12–16%
miscarriages and 3–5% congenital malformations.
109 110 In
contrast, no studies were found that evaluated the effect of
methotrexate for men on miscarriages/birth defects, male and
female fertility or on newborns during lactation. Nevertheless,
expert opinion is to stop methotrexate at least 3 months before
planned pregnancy in both men and women and not to use
methotrexate during pregnancy or breast feeding.
DISCUSSION
Ten multinational recommendations for the use of methotrex-
ate in daily clinical practice were developed, which are practical,
evidence-based and supported by a large panel of international
rheumatologists in the 3E Initiative.
The involvement of 751 rheumatologists from 17 countries
was unique in the development of the current recommenda-
tions. It allowed a selection of relevant topics, reflecting
frequently encountered questions on the use of methotrexate
in daily practice. Furthermore, a broad participation increases
external validity and enhances future dissemination and
implementation into rheumatological practice worldwide.
A second principal feature of the initiative was the systematic
literature research. Following a strict methodology, we aimed to
find all available evidence regarding each topic, which resulted
in a large number of reviewed articles. Although for some areas
little to no evidence was found, including (the frequency of)
toxicity monitoring, the timing of folic acid, non-orthopaedic
surgery and the effect of methotrexate on fertility and lactation,
the majority of the recommendations is supported by evidence
from RCT and high-quality cohort studies.
The same evidence, however, might limit the recommenda-
tions, as many studies were old and included longstanding RA
patients who received methotrexate in low dosages without
folic acid. As this may not reflect current clinical practice, the
results should be interpreted and extrapolated with caution. In
addition, patients’ participation and preferences may influence
the recommendations. Nevertheless, the recommendations are
based on currently available evidence and can be adjusted if
future studies or clinical experience reveal new insights.
In summary, multinational recommendations for the use of
methotrexate in daily clinical practice focussed on RA were
developed, integrating systematic literature review and expert
opinion, with the aim of promoting evidence-based medicine
and ultimately improving patient care.
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